/**
 * Supporting satellite for /china-medical-devices-market-report
 * Slug: /blog/china-device-vbp-rounds-explained
 */
import type { BlogPost } from '@/types/blog';
import { NMPA_CLASS_III_TIMELINE_SLUG } from '@/data/blog-nmpa-class-iii-timeline-2026';

export const CHINA_DEVICE_VBP_EXPLAINED_SLUG = 'china-device-vbp-rounds-explained';

export const CHINA_DEVICE_VBP_EXPLAINED_COVER_IMAGE =
  '/images/blog/china-device-vbp-rounds-explained-cover.jpg';

export const CHINA_DEVICE_VBP_EXPLAINED_META_TITLE =
  'China Device VBP 2026: Stents, Joints & Renewals | BioNixus';

export const CHINA_DEVICE_VBP_EXPLAINED_META_DESCRIPTION =
  'How China’s medical device Volume-Based Procurement works in 2026: stent and joint price-cut examples, win vs lose outcomes, renewals, and private-hospital escape valves.';

export const CHINA_DEVICE_VBP_EXPLAINED_DISPLAY_TITLE =
  'China Device VBP Rounds Explained 2026: Price Cuts, Volume Commitments & Localization';

export const CHINA_DEVICE_VBP_EXPLAINED_PUBLISHED_ISO = '2026-08-18T10:00:00.000Z';
export const CHINA_DEVICE_VBP_EXPLAINED_UPDATED_ISO = '2026-08-18T10:00:00.000Z';

export const CHINA_DEVICE_VBP_EXPLAINED_TAGS = [
  'VBP',
  'NHSA',
  'China',
  'Medical Devices',
  'Procurement',
  'Market Access',
] as const;

export const CHINA_DEVICE_VBP_EXPLAINED_TABLE_OF_CONTENTS: { heading: string; anchor: string }[] = [
  { heading: 'What device VBP is (and is not)', anchor: 'what-vbp-is' },
  { heading: 'Reference rounds: stents, joints, spine, EP', anchor: 'reference-rounds' },
  { heading: 'Win vs lose commercial outcomes', anchor: 'win-vs-lose' },
  { heading: 'Renewals, localization, and private channels', anchor: 'renewals-localization' },
];

export const CHINA_DEVICE_VBP_EXPLAINED_EXECUTIVE_SUMMARY_HTML = `<p><strong>Device VBP in one page for 2026 commercial planning</strong></p>
<ul>
<li><strong>Mechanism</strong> — NHSA-coordinated Volume-Based Procurement trades steep price cuts for multi-year public hospital volume commitments.</li>
<li><strong>Reference shocks</strong> — coronary stents ~93% price cuts; joint implants ~84% — still the mental model for how aggressive rounds can be.</li>
<li><strong>Win / lose</strong> — winners get volume at thin margin; losers face near-exclusion from public Grade III purchasing until renewal.</li>
<li><strong>Full market report</strong> — NMPA, segments, and companies live on the <a href="/china-medical-devices-market-report">China Medical Devices Market Report</a>.</li>
</ul>`;

export const CHINA_DEVICE_VBP_EXPLAINED_SCHEMA_FAQ: { question: string; answer: string }[] = [
  {
    question: 'What is medical device VBP in China?',
    answer:
      'Volume-Based Procurement is a centralized tendering mechanism run through NHSA and provincial procurement offices. Hospitals commit multi-year volume to winning suppliers in exchange for sharply reduced prices. Categories already included include coronary stents, joint implants, spine implants, and cardiac electrophysiology catheters, with further expansion expected.',
  },
  {
    question: 'What happens if a manufacturer loses a China device VBP round?',
    answer:
      'Losing often means near-exclusion from public hospital purchasing in that category until the next renewal window. Residual revenue may shift to private hospitals, non-VBP provinces, or adjacent SKUs still on routine provincial GPO tenders.',
  },
  {
    question: 'Do private hospitals follow national device VBP prices?',
    answer:
      'Private and premium hospitals are a partial escape valve and are less bound by national VBP award lists, especially for cash-pay or commercial-insurance episodes. Absolute procedure volume, however, remains concentrated in public Grade III hospitals, so most multinationals still need a VBP strategy for public share.',
  },
];

export const CHINA_DEVICE_VBP_EXPLAINED_BODY_HTML = `<p>China’s medical device Volume-Based Procurement (VBP) is the main commercial shock for consumable-heavy categories in the public hospital channel. Understanding win vs lose outcomes matters more than memorizing every historical tender date — renewals keep reopening competition.</p>

<p>For NMPA pathways, segment tables, and company landscape, see the canonical <a href="/china-medical-devices-market-report">China Medical Devices Market Report 2026</a>.</p>

<h2 id="what-vbp-is">What device VBP is (and is not)</h2>
<p>VBP is not ordinary provincial GPO tendering. It is a high-volume, multi-year commitment mechanism: public hospitals lock volume at VBP prices; manufacturers that win secure share at compressed margins; manufacturers that lose are often shut out of that public category. Capital equipment such as CT/MRI remains largely gated by large-equipment configuration licensing rather than consumable-style VBP, though DRG/DIP payment reform still pushes hospitals toward lower-cost devices inside episode payments.</p>

<h2 id="reference-rounds">Reference rounds: stents, joints, spine, EP</h2>
<p>Reference shocks still frame commercial expectations:</p>
<ul>
<li><strong>Coronary stents (2020)</strong> — prices cut by roughly 93% (illustrative average from ~CNY 13,000 to ~CNY 700)</li>
<li><strong>Joint replacements (2021)</strong> — knee implants cut by roughly 84%</li>
<li><strong>Spine implants</strong> — extended under VBP from 2023</li>
<li><strong>Cardiac electrophysiology catheters</strong> — national/provincial rounds from 2024</li>
</ul>
<p>Treat these as directionally accurate public-reporting examples, not a substitute for category-specific tender documents in the year you bid.</p>

<h2 id="win-vs-lose">Win vs lose commercial outcomes</h2>
<p><strong>Win:</strong> multi-year public volume at thin margin; manufacturing and working capital must scale to awarded volumes.<br />
<strong>Lose:</strong> near-exclusion from Grade III public purchasing in that SKU family; dual-channel plans (private premium + non-VBP provinces) become survival paths until renewal.</p>
<p>Localization and joint-venture manufacturing increasingly act as tender-scoring levers under import-substitution catalogues, even when clinical performance is comparable to pure imports.</p>

<h2 id="renewals-localization">Renewals, localization, and private channels</h2>
<p>VBP is iterative. Prior winners still face renewal tenders; new categories keep being added. Private hospitals can preserve some premium pricing but cannot replace public volume. For GCC teams comparing China compression with Gulf premium procurement, see the <a href="/gcc-medical-devices-market-report">GCC Medical Devices Market Report</a> and the <a href="/healthcare-market-research">healthcare market research hub</a>.</p>
<p>Related: <a href="/blog/nmpa-class-iii-registration-timeline-2026">NMPA Class III registration timeline 2026</a>.</p>`;

export const CHINA_DEVICE_VBP_EXPLAINED_HARDCODED_POST: BlogPost = {
  id: 'hardcoded-china-device-vbp-explained',
  slug: CHINA_DEVICE_VBP_EXPLAINED_SLUG,
  title: CHINA_DEVICE_VBP_EXPLAINED_DISPLAY_TITLE,
  excerpt:
    'China medical device VBP rounds explained for 2026: stent and joint price-cut examples, win vs lose outcomes, renewals, localization scoring, and private-hospital escape valves.',
  date: '18 Aug 2026',
  category: 'Market Intelligence',
  country: 'China',
  language: 'en',
  readingTime: 7,
  tags: [...CHINA_DEVICE_VBP_EXPLAINED_TAGS],
  coverImage: CHINA_DEVICE_VBP_EXPLAINED_COVER_IMAGE,
  ogImage: CHINA_DEVICE_VBP_EXPLAINED_COVER_IMAGE,
  ogTitle: CHINA_DEVICE_VBP_EXPLAINED_META_TITLE,
  ogDescription: CHINA_DEVICE_VBP_EXPLAINED_META_DESCRIPTION,
  seoMetaTitle: CHINA_DEVICE_VBP_EXPLAINED_META_TITLE,
  seoMetaDescription: CHINA_DEVICE_VBP_EXPLAINED_META_DESCRIPTION,
  seoCanonicalUrl: `https://www.bionixus.com/blog/${CHINA_DEVICE_VBP_EXPLAINED_SLUG}`,
  authorName: 'Laura Williams',
  authorTitle: 'Research Director, BioNixus Healthcare Market Research',
  publishedAtIso: CHINA_DEVICE_VBP_EXPLAINED_PUBLISHED_ISO,
  updatedAtIso: CHINA_DEVICE_VBP_EXPLAINED_UPDATED_ISO,
  tableOfContents: CHINA_DEVICE_VBP_EXPLAINED_TABLE_OF_CONTENTS,
  executiveSummary: CHINA_DEVICE_VBP_EXPLAINED_EXECUTIVE_SUMMARY_HTML,
  faq: [...CHINA_DEVICE_VBP_EXPLAINED_SCHEMA_FAQ],
  ctaSection: {
    title: 'Comparing China VBP pressure with GCC premium procurement?',
    description:
      'BioNixus delivers China and GCC device procurement intelligence so commercial teams can rebalance portfolios between volume-compressed and premium hospital markets.',
    buttonText: 'Talk to BioNixus',
    buttonUrl: 'https://www.bionixus.com/contact',
  },
  body: CHINA_DEVICE_VBP_EXPLAINED_BODY_HTML,
};

/**
 * Off-page distribution checklist (Phase 4) — execute after deploy; do not buy links.
 */
export const CHINA_DEVICES_SERP_DISTRIBUTION_PLAN = {
  canonicalUrl: 'https://www.bionixus.com/china-medical-devices-market-report',
  satellites: [
    `https://www.bionixus.com/blog/${NMPA_CLASS_III_TIMELINE_SLUG}`,
    `https://www.bionixus.com/blog/${CHINA_DEVICE_VBP_EXPLAINED_SLUG}`,
  ],
  linkedIn: {
    angle:
      'Issue-style brief: NMPA Class I–III + NHSA VBP (stents ~93% / joints ~84%) with link to the China devices report as the hub.',
    cta: 'Comment “China devices” or DM for GCC comparator framing.',
  },
  newsletter: {
    subject: 'China devices 2026: NMPA, VBP shocks, and what to do next',
    bodyFocus: 'Unique NMPA/VBP insight + deep link to report; satellites for Class III timeline and VBP explained.',
  },
  digitalPr: {
    asset: 'One original VBP price-cut timeline graphic for medtech trade roundups',
    avoid: 'Paid links, doorway clones, duplicate “market report” thin pages',
  },
  partnerCites:
    'Ask GCC/MENA clients and consultants to cite the China page as the APAC comparator from BioNixus GCC device content.',
} as const;
